| Autor: |
Amit Roy, Randall J. Brenneman, Jacob Hogan, Justin M. Barnes, Yi Huang, Robert Morris, Sreekrishna Goddu, Michael Altman, Jose Garcia-Ramirez, Harold Li, Jacqueline E. Zoberi, Arnold Bullock, Eric Kim, Zachary Smith, Robert Figenshau, Gerald L. Andriole, Brian C. Baumann, Jeff M. Michalski, Hiram A. Gay |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Clinical and Translational Radiation Oncology, Vol 29, Iss , Pp 47-53 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2405-6308 |
| DOI: |
10.1016/j.ctro.2021.05.004 |
| Popis: |
Background: We present the first report comparing early toxicity outcomes with high-dose rate brachytherapy (HDR-BT) boost upfront versus intensity modulated RT (IMRT) upfront combined with androgen deprivation therapy (ADT) as definitive management for intermediate risk or higher prostate cancer. Methods and Materials: We reviewed all non-metastatic prostate cancer patients who received HDR-BT boost from 2014 to 2019. HDR-BT boost was offered to patients with intermediate-risk disease or higher. ADT use and IMRT target volume was based on NCCN risk group. IMRT dose was typically 45 Gy in 25 fractions to the prostate and seminal vesicles ± pelvic lymph nodes. HDR-BT dose was 15 Gy in 1 fraction, delivered approximately 3 weeks before or after IMRT. The sequence was based on physician preference. Biochemical recurrence was defined per ASTRO definition. Gastrointestinal (GI) and Genitourinary (GU) toxicity was graded per CTCAE v5.0. Pearson Chi-squared test and Wilcoxon tests were used to compare toxicity rates. P-value |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
